Neglected tropical diseases
1.7 billion people need treatment for diseases that get under 2% of pharmaceutical R&D and falling aid.
The prize at the limit
The lowest ceiling on this board, and the honest number rather than a flattering one. The disease burden is enormous and the science is largely solved: ivermectin, azithromycin and praziquantel work and cost cents. The binding constraint is that the patients cannot pay, so the winning organisation is a donation-funded distribution programme, not an equity story. This is the clearest case on the index where enormous human value and a small in-limit cap sit on the same row.
comparable: a mid-cap specialty pharma unit, not a major · confidence low · a ceiling, not a forecast
The summary lives here. The full whitepaper walks through the four-axis ranking, existing alternatives, proposed direction, cost & scale, and suggested investors — in the spirit of Hyperloop Alpha.
Quantity · humans affected
Severity · WTP / wealth
share of affected person’s wealth they would pay for a solution
Current solutions
quality of existing solutions — low score = high opportunity
Market size · TAM
USD — addressable diagnostics + therapeutics market at full coverage the world is already paying
Time · OOM to impact
order-of-magnitude horizon to civilizational-scale impact
Priority score
38
importance × urgency, 0–100
Importance
65
humans affected × severity, gated by market
Urgency
58
direction of travel + solution gap
Neglectedness
8/10ODA fell 41% in five years and NTDs receive under 2% of pharmaceutical R&D, despite affecting more people than any single disease category tracked by WHO.
highTractability
7/10Interventions are cheap and proven (mass drug administration, existing therapeutics); the binding constraint is financing and delivery logistics, not new science.
medWays to help
Build pooled-procurement platforms, cold-chain-free diagnostics, or field logistics for last-mile drug delivery.
Push to restore NTD ODA funding cut over 2018–2023.
Organizations
People to follow
- Peter Hotezpresident, Sabin Vaccine Institute; dean, Baylor National School of Tropical Medicine
Three-lens scoring
Neglected tropical diseases cause chronic disability, stigma, and impoverishment across more than 1.7 billion people, yet the commercial market for new diagnostics and medicines is structurally weak: successful control shrinks the market, patients are largely poor, and delivery is hard. Official development assistance for NTDs fell 41% between 2018 and 2023 even as interventions remain some of the cheapest in global health — mass drug administration often costs under a dollar per person per year. This is not a science-discovery problem, it is a market-failure and delivery-financing problem: pooled procurement, target product profiles, milestone prizes, and stabilized field logistics could close most of the gap with tools that already exist.
The success vision · 10 years horizon
If we solve this, here is the world we get.
Before · today
1.7B people need NTD interventions. ODA fell 41% 2018–2023. NTDs receive under 2% of pharmaceutical R&D investment despite the population affected.
After · 10 years
Mass drug administration reaches 90%+ coverage in endemic areas via pooled procurement and stabilized financing; several NTDs (following guinea worm and trachoma) are fully eliminated; a durable innovation pipeline replaces one-off donation drives.
Companies on this quest
0 mappedNo companies mapped yet. Known gap.
Capital funding this quest
0 allocatorsNo allocators mapped yet. Known gap.
Writing about this right now
full feed →No coverage logged yet. The next ingest cron will populate this.